Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | TACR3 | P29371 | 12/20 | 0.43 |
| ▸ | TACR2 | P21452 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3024362 | 0.92 | TACR3 (0.46) | SLC2A1TACR3TACR2TLR7SMN1; SMN2 | |
| SCHEMBL3038770 | 0.91 | TACR3 (0.46) | SLC2A1TACR3TACR2TLR7SMN1; SMN2 | |
| SCHEMBL4357027 | 0.85 | TACR3 (0.46) | SLC2A1TACR3TACR2 | |
| SCHEMBL3035533 | 0.85 | TACR3 (0.41) | SLC2A1TACR3TLR7SMN1; SMN2MAPT | |
| SCHEMBL4361680 | 0.85 | TACR3 (0.45) | SLC2A1TACR3TACR2 | |
| SCHEMBL4358870 | 0.82 | TACR3 (0.43) | SLC2A1TACR3TACR2TP53MAPT | |
| SCHEMBL3037099 | 0.81 | TACR3 (0.45) | SLC2A1TACR3RXFP1SMN1; SMN2MAPT | |
| SCHEMBL4363718 | 0.80 | TACR3 (0.43) | SLC2A1TACR3TACR2 | |
| SCHEMBL4351001 | 0.79 | TACR3 (0.38) | SLC2A1TACR3TP53RXFP1IGF1R | |
| SCHEMBL4359090 | 0.78 | KMT2A (0.40) | SLC2A1TACR3IGF1RMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216837-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100216837-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100216837-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| EP-1874721-A2 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006067414-A2 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006067414-A2 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216837-A1 | GLYCINE TRANSPORT INHIBITORS | SLC18A2, SLC6A5, SLC1A2 | SLC2A1 46/4885TACR3 1572/4885TACR2 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.